2-苄氧基-5-溴嘧啶 | 742058-39-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-苄氧基-5-溴嘧啶
• 中文别名: 2-苄氧基-5溴嘧啶；2-苄氧基-5-溴嘧啶,95%
• 英文名称: 2-(benzyloxy)-5-bromopyrimidine
• 英文别名: 5-bromo-2-phenylmethoxypyrimidine
• CAS: 742058-39-5
• 化学式: C₁₁H₉BrN₂O
• 分子量: 265.109
• InChiKey: RDGZEALFIOPSCC-UHFFFAOYSA-N

物化性质

• 熔点：
  100-103°C
• 沸点：
  392.6±44.0 °C(Predicted)
• 密度：
  1.499±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存于室温下，密封保存，并确保环境干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Benzyloxy-5-bromopyrimidine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Benzyloxy-5-bromopyrimidine
Ingredient name:
CAS number: 742058-39-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H9BrN2O
Molecular weight: 265.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苄氧基-5-溴嘧啶 在 ammonium hydroxide 、 copper(l) iodide 、 potassium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 18.0h， 以60%的产率得到2-(benzyloxy)pyrimidin-5-amine
  参考文献：
  名称：

  [EN] BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS
  [FR] COMPOSÉS BIFONCTIONNELS ET LEUR UTILISATION POUR RÉDUIRE LES TAUX D'ACIDE URIQUE

  摘要：

  具有双重功能的化合物可以增加尿酸排泄并减少尿酸产生。提供了使用这些化合物来降低血液或血清中尿酸水平、治疗尿酸代谢紊乱疾病以及维持血液或血清中正常尿酸水平的方法。同时还提供了含有这些双功能化合物的药物组合物。

  公开号：

  WO2015123003A1
• 作为产物：
  描述：

  5-溴-2-氯嘧啶 、 苯甲醇 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 12.17h， 以97%的产率得到2-苄氧基-5-溴嘧啶
  参考文献：
  名称：

  一些新的2,5-二取代嘧啶衍生物的抗癌活性及其合成和细胞毒性评估

  摘要：

  摘要已经报道了2，5-二取代的嘧啶的有效合成方法。通过在有0.5 M Na 2 CO 3水溶液的催化量的PdCl 2（PPh 3）2存在下，将2-取代的苄氧基-5-溴嘧啶与各种芳基硼酸进行Suzuki偶联，获得所需的2,5-取代的嘧啶。在80°C下。然后在CH 3 CN：DMF（1：1）中，在Cs 2 CO 3存在下，通过2-氯-5-溴嘧啶与取代的苄醇的反应合成2-苄氧基-5-溴嘧啶。一些2，5-二取代的嘧啶已显示出对HeLa细胞系的中等体外细胞毒活性。 图形概要

  DOI：

  10.1007/s00044-014-1276-6

文献信息

• [EN] ETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017021384A1

  公开（公告）日：2017-02-09

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, F or CI; L is a bond or lower alkylene; R2 is -(CH2)nO-lower alkyl, lower alkyl substituted by halogen, -(CH2)nC(0)0-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, =0, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by -(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or -(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof. The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

  本发明涉及以下式(I)的化合物，其中R1是氢、F或Cl；L是键或较低的烷基；R2是-(CH2)nO-较低烷基、受卤素取代的较低烷基、-(CH2)nC(0)0-较低烷基、受较低烷基或卤素取代的苯基、或是5或6-成员杂环芳基，选自吡啶基、嘧啶基、吡啉基、噻唑基、咪唑基、吡唑基或三唑基，可以选择地受较低烷基、卤素、较低烷氧基、=0、苄氧基、环烷氧基、羟基、氰基、受卤素取代的较低烷基、或者是-(CH2)nO-较低烷基取代；n为1、2或3；R3是氢、较低烷基或-(CH2)nO-较低烷基；R4是苯基、吡啶基或嘧啶基，可以选择地受F取代；Y是CF或CCl；或者是其药学上可接受的盐或酸加合盐，或者是外消旋混合物，或者是其对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗帕金森病、焦虑、呕吐、强迫症、自闭症、神经保护、癌症、抑郁症和2型糖尿病。
• [EN] BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS<br/>[FR] DERIVES DE BIS(HETERO)ARYLE CARBOXAMIDE DESTINES A ETRE UTILISES EN TANT QU'ANTAGONISTES DE LA PG12
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004069805A1

  公开（公告）日：2004-08-19

  The present invention relates to aryl or heteroaryl amido alkane derivatives of formula (I) wherein R6 represents carboxy or tetrazolyl, which are useful as an active ingredient of pharmaceutical preparations. The aryl or heteroaryl amido alkanes of the present invention have PGI2 antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with PGI2 activity.Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases also relate to PGI2.

  本发明涉及式(I)的芳基或杂环芳基酰胺烷基衍生物，其中R6代表羧基或四唑基，其作为药物制剂的活性成分是有用的。本发明的芳基或杂环芳基酰胺烷基具有PGI2拮抗活性，可用于预防和治疗与PGI2活性相关的疾病。这些疾病包括泌尿系统疾病或障碍，如：膀胱出口梗阻、膀胱过度活跃、尿失禁、膀胱逼尿肌过度反射、膀胱逼尿肌不稳定、膀胱容量减少、排尿频率增加、急迫性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺增生（BPH）、前列腺炎、尿频、夜尿、尿急、盆腔过敏、尿道炎、盆腔疼痛综合征、前列腺疼痛综合征、膀胱炎或特发性膀胱过敏。本发明的化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病性疼痛、急性疼痛、慢性疼痛、牙痛、经前疼痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为这些疾病也与PGI2有关。
• Design, Synthesis, and Implementation of Sodium Silylsilanolates as Silyl Transfer Reagents
  作者：Hiroki Yamagishi、Hayate Saito、Jun Shimokawa、Hideki Yorimitsu

  DOI：10.1021/acscatal.1c02733

  日期：2021.8.20

  There is an increasing demand for facile delivery of silyl groups onto organic bioactive molecules. One of the common methods of silylation via a transition-metal-catalyzed coupling reaction employs hydrosilane, disilane, and silylborane as major silicon sources. However, the labile nature of the reagents or harsh reaction conditions sometimes render them inadequate for the purpose. Thus, a more versatile

  对将甲硅烷基轻松传递到有机生物活性分子上的需求不断增加。通过过渡金属催化偶联反应进行硅烷化的一种常用方法是使用氢硅烷、乙硅烷和甲硅烷基硼烷作为主要的硅源。然而，试剂的不稳定性质或苛刻的反应条件有时使其不适合该目的。因此，需要更通用的甲硅烷基替代来源。我们在此报告了可储存的甲硅烷基硅烷醇钠的设计、合成和实施，该钠可用于在钯催化剂存在下芳基卤化物和拟卤化物的甲硅烷基化。所开发的方法允许对具有各种甲硅烷基的多官能化合物进行后期官能化。
• Highly stereoselective synthesis of aryl/heteroaryl-<i>C</i>-nucleosides <i>via</i> the merger of photoredox and nickel catalysis
  作者：Yingying Ma、Shihui Liu、Yifan Xi、Hongrui Li、Kai Yang、Zhihao Cheng、Wei Wang、Yongqiang Zhang

  DOI：10.1039/c9cc07184a

  日期：——

  developed. The reaction proceeds smoothly under visible-light irradiation and features the using of cost-effective and easily handled catalysts and starting materials, which allows the highly stereoselective synthesis of diverse aryl/heteroaryl-C-nucleosides in moderate to high yields.

  已经开发了异核糖基/脱氧核糖基酸与芳基/杂芳基溴化物的光氧化还原/镍双催化的脱羧交叉偶联反应。该反应在可见光照射下可顺利进行，其特点是使用经济高效且易于操作的催化剂和起始原料，从而可以以中等至高收率高度立体选择性地合成各种芳基/杂芳基-C-核苷。
• [EN] CERTAIN PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE CERTAINES PROTÉINES KINASES
  申请人：CHONGQING FOCHON PHARMACEUTICAL CO LTD

  公开号：WO2017114351A1

  公开（公告）日：2017-07-06

  Provided are certain CDK4/6 inhibitors, pharmaceutical compositions, and medthods of use thereof.

  提供了某些CDK4/6抑制剂、药物组成和使用方法。